Reviewing OptiNose (OPTN) and Editas Medicine (NASDAQ:EDIT) – TrueBlueTribune
|
Reviewing OptiNose (OPTN) and Editas Medicine (NASDAQ:EDIT)
TrueBlueTribune It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … OptiNose (OPTN) vs. Editas Medicine (EDIT) Head-To-Head Analysis |
